Business
Presenting at Next-Gen Immuno-Oncology Conference
Presenting at Next-Gen Immuno-Oncology Conference.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n04 March 2024\n \n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nScancell to present at the Next-Gen Immuno-Oncology Conference\n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that it will be presenting at the Next-Gen Immuno-Oncology Conference. The conference is being held from 7-8 March 2024 in London, UK.\n \nProfessor Lindy Durrant, Chief Executive Officer of Scancell, will be speaking at the \"New Antibody Formats & Cell Therapy\" session titled \"A novel redirecting antibody targeting SCLC\" which will take place from 2:45 pm - 3:15 pm GMT on Thursday 7 March 2024.\n \nProfessor Lindy Durrant, Chief Executive Officer of Scancell, said: \"I am looking forward to presenting our preclinical results showing strong anti-tumour killing with no associated toxicity with our innovative T cell redirecting antibody at this premier event which is dedicated to advancing the field of immuno-oncology\".\n \nIf you would like to arrange a meeting with management, please contact [email protected].\n \n-ENDS-\n \n\n\n\n\nFor further information, please contact:\n\n\n\n\n\n\n\nScancell Holdings plc\n\n\n+44 (0) 20 3709 5700\n\n\n\n\nProfessor Lindy Durrant, CEO\n \nDr Jean-Michel Cosséry, Non-Executive Chairman\n \n\n\n\n\n\n\n\nStifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)\n\n\n+44 (0) 20 7710 7600\n\n\n\n\nNicholas Moore/Samira Essebiyea (Healthcare Investment Banking)\n\n\n \n\n\n\n\nNick Adams/Nick Harland (Corporate Broking)\n \n\n\n \n\n\n\n\nWG Partners LLP (Joint Broker)\n\n\n+44 (0) 20 3705 9330\n\n\n\n\nDavid Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby\n \n\n\n\n\n\n\n\nPanmure Gordon (UK) Limited (Joint Broker)\n\n\n+44 (0) 20 7886 2500\n\n\n\n\nFreddy Crossley/Emma Earl (Corporate Finance)\n\n\n \n\n\n\n\nRupert Dearden (Corporate Broking)\n\n\n \n\n\n\n\n \n\n\n\n\nICR Consilium\n\n\n+44 (0) 20 3709 5700\n\n\n\n\nMary-Jane Elliott/Matthew Neal/Chris Welsh\n\n\[email protected]\n \n\n\n\n\n \nAbout Scancell\n \nScancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the hu...